Skip to content

A Study to Evaluate the Cooling Sensation and Consumer Liking of a Skin Disinfectant Spray

A Study to Evaluate the Cooling Sensation and Consumer Liking of a Skin Disinfectant Spray

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02106403
Enrollment
50
Registered
2014-04-08
Start date
2014-05-31
Completion date
2014-06-30
Last updated
2015-02-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Skin Care

Brief summary

The objective of this randomised, examiner and subject blinded study is to evaluate and compare cooling performance and overall consumer liking of the prototype formulation with the currently marketed wound spray and negative control in subjects with experimental wounds. For each subject, three superficial wounds will be induced on two volar forearms, by sequential tape strippings until a glistening layer is visualized. After wounding, a randomised test product will be sprayed twice on test site, and the subject will be asked to complete a questionnaire evaluating product cooling performance and overall liking.

Interventions

OTHERPrototype disinfectant spray formulation

0.13% w/w BAC and 1% MGA. After wounding, the product will be held approximately 10 cm above the wounding area, and sprayed twice towards the wound

OTHERReference product

0.13% w/w BAC. After wounding, the product will be held approximately 10 cm above the wounding area, and sprayed twice towards the wound

OTHERNegative control

0.9% w/v sodium chloride solution. After wounding, the product will be held approximately 10 cm above the wounding area, and sprayed twice towards the wound

Sponsors

GlaxoSmithKline
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

* Participants in good health with healthy and intact skin on the test area * Age 18-60 years

Exclusion criteria

* Pregnancy or breast-feeding * Allergy/Intolerance * Participants currently taking any topical or systemic treatments that may interfere with or mask the test results * Participants who have taken any topical anti-inflammation treatment in the application area in past 2 months * Participants who are vulnerable to any intervention * Damaged skin close to test site, active skin disorders, any visible skin disorder

Design outcomes

Primary

MeasureTime frameDescription
Participant-perceived Cooling Sensation at 15 MinAt 15 min after product applicationThe cooling sensation was assessed on VAS (0-100 mm, where 0= no cooling and 100= extreme cooling) at 15 min post study product application.
Participant-perceived Cooling Sensation Immediately Post Product ApplicationImmediately after product applicationThe cooling sensation was assessed immediately after the study product application on 100 millimeter (mm) Visual Analogue Scale (VAS) (0-100 mm, where 0= no cooling and 100= extreme cooling).
Participant-perceived Cooling Sensation at 3 MinAt 3 min after product applicationThe cooling sensation was assessed on VAS (0-100 mm, where 0= no cooling and 100= extreme cooling) at 3 min post study product application.
Participant-perceived Cooling Sensation at 5 MinAt 5 min after product applicationThe cooling sensation was assessed on VAS (0-100 mm, where 0= no cooling and 100= extreme cooling) at 5 min post study product application.

Secondary

MeasureTime frameDescription
Overall Sensory Liking of Study ProductsImmediatey, 3 min, 5 min and 15 min after product applicationOverall sensory liking of the study products was assessed immediately, 3min, 5 min and 15 min after products application. The assessment was done on a 9 point categorical scale where 1= Dislike it extremely, 2= Dislike it very much, 3= Dislike it moderately, 4= Dislike it slightly, 5= Neither like it nor dislike it, 6= Like it slightly, 7= Like it moderately, 8= Like it very much, 9= Like it extremely.

Countries

China

Participant flow

Recruitment details

Partcipants were recruited at one clinical study site in China.

Pre-assignment details

A total of 50 participants with 1:1 ratio of male to female were screened and 50 were randomized.

Participants by arm

ArmCount
All Randomized Participants
All randomized participants were evaluated for baseline characteristics
50
Total50

Withdrawals & dropouts

PeriodReasonFG000FG001FG002FG003FG004FG005
Follow-Up Visit 3Other Reason000001

Baseline characteristics

CharacteristicAll Randomized Participants
Age, Continuous40.0 Years
STANDARD_DEVIATION 12.32
Sex: Female, Male
Female
25 Participants
Sex: Female, Male
Male
25 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
deaths
Total, all-cause mortality
— / —— / —— / —
other
Total, other adverse events
1 / 501 / 501 / 50
serious
Total, serious adverse events
0 / 500 / 500 / 50

Outcome results

Primary

Participant-perceived Cooling Sensation at 15 Min

The cooling sensation was assessed on VAS (0-100 mm, where 0= no cooling and 100= extreme cooling) at 15 min post study product application.

Time frame: At 15 min after product application

Population: Efficacy analysis was based on intent-to-treat (ITT) population defined as all randomized participants who received the product at least once and provided at least one post product use assessment of efficacy. One participant had one efficacy assessment outside the required time window but was included in ITT population

ArmMeasureValue (LEAST_SQUARES_MEAN)Dispersion
Prototype Disinfectant Spray FormulationParticipant-perceived Cooling Sensation at 15 Min16.84 Score on a scaleStandard Error 2.725
Reference ProductParticipant-perceived Cooling Sensation at 15 Min12.45 Score on a scaleStandard Error 2.725
Negative ControlParticipant-perceived Cooling Sensation at 15 Min10.43 Score on a scaleStandard Error 2.725
Comparison: The null and alternative hypotheses were: H0: product difference was null vs. Ha: product difference was not null.p-value: 0.035795% CI: [0.44, 12.38]ANOVA
Comparison: The null and alternative hypotheses were: H0: product difference was null vs. Ha: product difference was not null.p-value: 0.50395% CI: [-3.95, 8]ANOVA
Comparison: The null and alternative hypotheses were: H0: product difference was null vs. Ha: product difference was not null.p-value: 0.148295% CI: [-1.59, 10.36]ANOVA
Primary

Participant-perceived Cooling Sensation at 3 Min

The cooling sensation was assessed on VAS (0-100 mm, where 0= no cooling and 100= extreme cooling) at 3 min post study product application.

Time frame: At 3 min after product application

Population: Efficacy analysis was based on intent-to-treat (ITT) population defined as all randomized participants who received the product at least once and provided at least one post product use assessment of efficacy. One participant had one efficacy assessment outside the required time window but was included in ITT population

ArmMeasureValue (LEAST_SQUARES_MEAN)Dispersion
Prototype Disinfectant Spray FormulationParticipant-perceived Cooling Sensation at 3 Min39.15 Score on a scaleStandard Error 3.726
Reference ProductParticipant-perceived Cooling Sensation at 3 Min29.42 Score on a scaleStandard Error 3.726
Negative ControlParticipant-perceived Cooling Sensation at 3 Min27.73 Score on a scaleStandard Error 3.726
Comparison: The null and alternative hypotheses were: H0: product difference was null vs. Ha: product difference was not null.p-value: 0.001695% CI: [4.43, 18.42]ANOVA
Comparison: The null and alternative hypotheses were: H0: product difference was null vs. Ha: product difference was not null.p-value: 0.632395% CI: [-5.31, 8.69]ANOVA
Comparison: The null and alternative hypotheses were: H0: product difference was null vs. Ha: product difference was not null.p-value: 0.006995% CI: [2.74, 16.73]ANOVA
Primary

Participant-perceived Cooling Sensation at 5 Min

The cooling sensation was assessed on VAS (0-100 mm, where 0= no cooling and 100= extreme cooling) at 5 min post study product application.

Time frame: At 5 min after product application

Population: Efficacy analysis was based on intent-to-treat (ITT) population defined as all randomized participants who received the product at least once and provided at least one post product use assessment of efficacy. One participant had one efficacy assessment outside the required time window but was included in ITT population

ArmMeasureValue (LEAST_SQUARES_MEAN)Dispersion
Prototype Disinfectant Spray FormulationParticipant-perceived Cooling Sensation at 5 Min34.46 Score on a scaleStandard Error 3.147
Reference ProductParticipant-perceived Cooling Sensation at 5 Min20.14 Score on a scaleStandard Error 3.147
Negative ControlParticipant-perceived Cooling Sensation at 5 Min22.32 Score on a scaleStandard Error 3.147
Comparison: The null and alternative hypotheses were: H0: product difference was null vs. Ha: product difference was not null.p-value: <0.000195% CI: [6.23, 18.04]ANOVA
Comparison: The null and alternative hypotheses were: H0: product difference was null vs. Ha: product difference was not null.p-value: 0.464595% CI: [-8.09, 3.72]ANOVA
Comparison: The null and alternative hypotheses were: H0: product difference was null vs. Ha: product difference was not null.p-value: <0.000195% CI: [8.41, 20.22]ANOVA
Primary

Participant-perceived Cooling Sensation Immediately Post Product Application

The cooling sensation was assessed immediately after the study product application on 100 millimeter (mm) Visual Analogue Scale (VAS) (0-100 mm, where 0= no cooling and 100= extreme cooling).

Time frame: Immediately after product application

Population: Efficacy analysis was based on intent-to-treat (ITT) population defined as all randomized participants who received the product at least once and provided at least one post product use assessment of efficacy. One participant had one efficacy assessment outside the required time window but was included in ITT population

ArmMeasureValue (LEAST_SQUARES_MEAN)Dispersion
Prototype Disinfectant Spray FormulationParticipant-perceived Cooling Sensation Immediately Post Product Application30.63 Score on a scaleStandard Error 4.345
Reference ProductParticipant-perceived Cooling Sensation Immediately Post Product Application30.15 Score on a scaleStandard Error 4.345
Negative ControlParticipant-perceived Cooling Sensation Immediately Post Product Application25.16 Score on a scaleStandard Error 4.345
Comparison: The null and alternative hypotheses were: H0: product difference was null vs. Ha: product difference was not null.p-value: 0.065995% CI: [-0.37, 11.29]ANOVA
Comparison: The null and alternative hypotheses were: H0: product difference was null vs. Ha: product difference was not null.p-value: 0.092895% CI: [-0.84, 10.81]ANCOVA
Comparison: The null and alternative hypotheses were: H0: product difference was null vs. Ha: product difference was not null.p-value: 0.871195% CI: [-5.35, 6.31]ANOVA
Secondary

Overall Sensory Liking of Study Products

Overall sensory liking of the study products was assessed immediately, 3min, 5 min and 15 min after products application. The assessment was done on a 9 point categorical scale where 1= Dislike it extremely, 2= Dislike it very much, 3= Dislike it moderately, 4= Dislike it slightly, 5= Neither like it nor dislike it, 6= Like it slightly, 7= Like it moderately, 8= Like it very much, 9= Like it extremely.

Time frame: Immediatey, 3 min, 5 min and 15 min after product application

Population: Efficacy analysis was based on intent-to-treat (ITT) population defined as all randomized participants who received the product at least once and provided at least one post product use assessment of efficacy. One participant had one efficacy assessment outside the required time window but was included in ITT population

ArmMeasureValue (LEAST_SQUARES_MEAN)Dispersion
Prototype Disinfectant Spray FormulationOverall Sensory Liking of Study Products6.60 Score on a scaleStandard Error 0.199
Reference ProductOverall Sensory Liking of Study Products6.38 Score on a scaleStandard Error 0.199
Negative ControlOverall Sensory Liking of Study Products6.22 Score on a scaleStandard Error 0.199

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026